18F-Fluorocholine (18F-FCho) to Distinguish Necrosis From Recurrence in Brain Metastases
Not Applicable
Completed
- Conditions
- Brain Metastases
- Registration Number
- NCT02037945
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Brief Summary
The main purpose of this study is to determine the distribution of 18F Fluorocholine (18F-FCH) in the brain which can help distinguishing radiation-induced scarring from tumor regrowth. In addition, the study will measure levels of 18F-FCH in the blood and (if applicable) in the brain lesion tissue that is removed as part of the planned brain surgery.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 19
Inclusion Criteria
- Patient and/or guardian is able to provide written informed consent prior to study registration
- Age ≥ 21 years old
- Evolving brain lesions post SRS requiring neurosurgical resection (whether for symptomatic control or to establish pathology)
Exclusion Criteria
- Inability to undergo a MRI or PET scan (e.g., claustrophobia or metal implant)
- Pregnant or nursing female
- Unable to cooperate for PET/CT
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method to distinguish radiation necrosis from progressive tumor 1 year by comparing the PET imaging results to the surgical pathology
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States
Memorial Sloan Kettering Cancer Center🇺🇸New York, New York, United States